Navigation Links
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer

WASHINGTON, Aug. 30 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held biotechnology company, today announced that it has hired Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer.

Dr. Stogniew will be responsible for Prestwick's pre-clinical development, regulatory and patent activities around its portfolio of products including its lead product candidate, tetrabenazine, a highly selective and reversible dopamine depletor in Phase 3 clinical trials for potential use as a treatment for chorea associated with Huntington's Disease.

He joins Prestwick most recently from Zelos Therapeutics, where he was Executive Vice President of Development responsible for pre-clinical, regulatory and patent development.

"With 25 years focused on developing drugs and 25 patents to his name, Marty will immediately help Prestwick as we work to execute and enhance our pipeline," said George F. Horner III, President and Chief Executive Officer of Prestwick. "He has made a significant impact in the development of successful drugs such as Anidulafugin, Amifostine and Idarubicin -- all of which are now on the market and positively impacting patients' lives."

Dr. Stogniew worked with Mr. Horner at Vicuron Pharmaceuticals, Inc. as Executive Vice President of Scientific Affairs from 2001 to 2005 before Vicuron was purchased by Pfizer in 2005 for $1.9 billion. Prior to Vicuron, Dr. Stogniew served as Chief Scientific Officer at Next Pharmaceuticals, Inc. and as Vice President of Pharmaceutical Sciences at MedImmune. Dr. Stogniew holds a Ph.D. in Medicinal Chemistry and a B.S. in Pharmacy from the University of Maryland.

About Prestwick

Prestwick is currently managing a portfolio of pipeline product candidates being studied for CNS conditions with significant unmet needs, including Huntington's disease, Parkinson's disease, restless legs syndrome, schizophrenia, autism, Alzheimer's disease and sleep apnea.

Please go to for more information.

SOURCE Prestwick Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Traveling stem cell show continues state tour
2. AT&T - BellSouth merger: Revestiture continues
3. Madison biotech continues its climb
4. Brady continues growth through Asian acquisition
5. Transition continues to impact Third Wave financials
6. Line between big pharma, big biotech continues to blur
7. Wisconsin giant continues to dominate the health care IT market
8. API Software continues expansion
9. Third Wave continues molecular diagnostic focus with new CEO
10. Midwest Public-Sector Biotech Continues to Sizzle
11. Corona Optical Systems continues to excite investors
Post Your Comments:
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):